Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Geologica Closes Financing And Property Acquisition (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc NRIFF


Primary Symbol: MRVFF

Healthcare Drug Manufacturers - Specialty & Generic
Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Nuvo Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(1)
•••
Comment by Marathon11on Feb 15, 2017 3:05pm
189 Views
Post# 25850720

RE:RE:New presentation, drop in sales...

RE:RE:New presentation, drop in sales...A great question C99... Why no sales of the S. American rights - these don't need to wait for the Phase III test results; its only been three years now since the FDA approved P2% in the US. If, for the moment, we rule-our incompetence, then what could be the reason for no deal in all this time. Is it possible that there is an agreement principle for ROW rights or an acquisition pending positive P3 European results. The stock was carefully walked down to its current level and is being held there... I think the acquisition is a distinct possibility. We'll see. All above is just my humble opinion.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities